{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:49:16Z","timestamp":1740142156600,"version":"3.37.3"},"reference-count":26,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100012155","name":"Elite Researcher Grant Committee, National Institute for Medical Research Development (NIMAD), Tehran, Iran","doi-asserted-by":"publisher","award":["982672"],"award-info":[{"award-number":["982672"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>HER2 over-expression plays a crucial role in the cancer treatment protocol. This study\nevaluates the effectiveness of organic anion and cation transport inhibitors and substrate on the tumor uptake of\n99mTc-HYNIC-(Ser)3-LTVPWY radiotracer in SKOV-3 tumor-bearing nude mice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Before the injection of the radiolabeled peptide, SKOV-3 tumor-bearing nude mice were treated with furosemide,\ncimetidine, para-amino hippuric acid, and saline. The inhibition effects of the organic anion and cation\ntransport inhibitors were compared with the control group. In both treatment and control groups, the tumor and renal\naccumulation of radiopeptide in mice bearing SKOV-3 tumors were assessed in biodistribution and SPECT imaging\nstudies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The biodistribution and imaging results suggested that all treated groups showed a higher tumor and higher\nnormal tissue radioactivity compared to the control group. According to the tumor imaging study, the furosemidetreated\ngroup had slightly better tumor uptake and a higher tumor to muscle uptake ratio than other treatment groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>Administration of furosemide (an OAT inhibitor) increased radioactivity accumulation in the kidneys\nand blood and improved tumor radioactivity uptake. PAH (an anion transporter substrate) and cimetidine (an OCT\ninhibitor) have a minor effect on the accumulation of radioactivity in the kidneys and the acquired images.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200223666220113101004","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T13:13:12Z","timestamp":1642684392000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Influence of Kidneys Ion Transport Inhibitors on the Pharmacokinetic and\nTumor Uptake Behaviors of a HER2-targeted Small Size Radiolabeled Peptide"],"prefix":"10.2174","volume":"23","author":[{"given":"Nasrin Abbasi","family":"Gharibkandi","sequence":"first","affiliation":[{"name":"Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"},{"name":"Student Research\nCommittee, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Molavipordanjani","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Faculty of\nMedicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Mardanshahi","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Faculty of\nMedicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8055-8036","authenticated-orcid":true,"given":"Seyed Jalal","family":"Hosseinimehr","sequence":"additional","affiliation":[{"name":"Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0304-419x(94)90012-4","volume":"1198","author":"Hynes N.E.","year":"1994","unstructured":"Hynes N.E.; Stern D.F.; The biology of erbB-2\/neu\/HER-2 and its role in cancer. Biochim Biophys Acta 1994,1198(2-3),165-184","journal-title":"Biochim Biophys Acta"},{"key":"ref=2","first-page":"1","author":"Seidenfeld J.","year":"2008","unstructured":"Seidenfeld J.; Samsom D.J.; Rothenberg B.M.; Bonnell C.J.; Ziegler K.M.; Aronson N.; HER2 testing to manage patients with breast cancer or other solid tumors. Evid Rep Technol Assess (Full Rep) 2008(172),1-362","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1309\/VE7862V2646BR6EX","volume":"121","author":"Lal P.","year":"2004","unstructured":"Lal P.; Salazar P.A.; Hudis C.A.; Ladanyi M.; Chen B.; HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004,121(5),631-636","journal-title":"Am J Clin Pathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3816\/CBC.2008.n.047","volume":"8","author":"Park J.W.","year":"2008","unstructured":"Park J.W.; Neve R.M.; Szollosi J.; Benz C.C.; Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008,8(5),392-401","journal-title":"Clin Breast Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1158\/1078-0432.CCR-18-1976","volume":"26","author":"Pegram M.D.","year":"2020","unstructured":"Pegram M.D.; Miles D.; Tsui C.K.; Zong Y.; HER2-overexpressing\/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clin Cancer Res 2020,26(4),775-786","journal-title":"Clin Cancer Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2967\/jnumed.115.172031","volume":"57","author":"Ulaner G.A.","year":"2016","unstructured":"Ulaner G.A.; Hyman D.M.; Ross D.S.; Corben A.; Chandarlapaty S.; Goldfarb S.; McArthur H.; Erinjeri J.P.; Solomon S.B.; Kolb H.; Lyashchenko S.K.; Lewis J.S.; Carrasquillo J.A.; Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET\/CT. J Nucl Med 2016,57(10),1523-1528","journal-title":"J Nucl Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2967\/jnumed.109.062224","volume":"50","author":"McLarty K.","year":"2009","unstructured":"McLarty K.; Cornelissen B.; Cai Z.; Scollard D.A.; Costantini D.L.; Done S.J.; Reilly R.M.; Micro-SPECT\/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009,50(8),1340-1348","journal-title":"J Nucl Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","volume":"6","author":"S\u00f6rensen J.","year":"2016","unstructured":"S\u00f6rensen J.; Velikyan I.; Sandberg D.; Wennborg A.; Feldwisch J.; Tolmachev V.; Orlova A.; Sandstr\u00f6m M.; Lubberink M.; Olofsson H.; Carlsson J.; Lindman H.; Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET\/CT. Theranostics 2016,6(2),262-271","journal-title":"Theranostics"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"Keyaerts M.","year":"2016","unstructured":"Keyaerts M.; Xavier C.; Heemskerk J.; Devoogdt N.; Everaert H.; Ackaert C.; Vanhoeij M.; Duhoux F.P.; Gevaert T.; Simon P.; Schallier D.; Fontaine C.; Vaneycken I.; Vanhove C.; De Greve J.; Lamote J.; Caveliers V.; Lahoutte T.; Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 2016,57(1),27-33","journal-title":"J Nucl Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ejmech.2016.11.011","volume":"127","author":"Sabahnoo H.","year":"2017","unstructured":"Sabahnoo H.; Noaparast Z.; Abedi S.M.; Hosseinimehr S.J.; New small 99mTc-labeled peptides for HER2 receptor imaging. Eur J Med Chem 2017,127,1012-1024","journal-title":"Eur J Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ejmech.2018.08.029","volume":"157","author":"Khodadust F.","year":"2018","unstructured":"Khodadust F.; Corrigendum to \u201cAn improved (99m)Tc-HYNIC-(Ser)(3)-LTVSPWY peptide with EDDA\/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor\u201d. Eur J Med Chem 2018,157,782","journal-title":"Eur J Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104591","volume":"112","author":"Biabani Ardakani J.","year":"2020","unstructured":"Biabani Ardakani J.; Talebpour Amiri F.; Khorramimoghaddam A.; Abbasi A.; Molavipordanjani S.; Hosseinimehr S.J.; Preclinical pharmacokinetic, biodistribution, radiation dosimetry, and toxicity studies of 99mTc-HYNIC-(Ser)3-LTVPWY: A novel HER2-targeted peptide radiotracer. Regul Toxicol Pharmacol 2020,112","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1389557516666160808122335","volume":"17","author":"Torabizadeh S.A.","year":"2017","unstructured":"Torabizadeh S.A.; Hosseinimehr S.J.; The influence of co-ligands on improving tumor targeting of 99mTc-HYNIC conjugated peptides. Mini Rev Med Chem 2017,17(2),86-94","journal-title":"Mini Rev Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2967\/jnumed.111.101527","volume":"53","author":"Tolmachev V.","year":"2012","unstructured":"Tolmachev V.; Tran T.A.; Rosik D.; Sj\u00f6berg A.; Abrahms\u00e9n L.; Orlova A.; Tumor targeting using affibody molecules: Interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012,53(6),953-960","journal-title":"J Nucl Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","volume":"60","author":"Akizawa H.","year":"2008","unstructured":"Akizawa H.; Uehara T.; Arano Y.; Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 2008,60(12),1319-1328","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/09553002.2020.1704906","volume":"96","author":"Shahsavari S.","year":"2020","unstructured":"Shahsavari S.; Shaghaghi Z.; Abedi S.M.; Hosseinimehr S.J.; Evaluation of 99mTc-HYNIC-(ser)3-LTVPWY peptide for glioblastoma imaging. Int J Radiat Biol 2020,96(4),502-509","journal-title":"Int J Radiat Biol"},{"author":"Avan Z","key":"ref=17","doi-asserted-by":"publisher","unstructured":"Avan Z;  The potential usefulness of (99m)Tc-HYNIC-(Ser)(3)- LTVPWY peptide for predicting HER2 status alteration after chemotherapy in ovarian tumor-bearing mice. Cancer Biother. Radiopharm., 2020. Online ahead of print.","DOI":"10.1089\/cbr.2020.4004"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","volume":"51","author":"Vegt E.","year":"2010","unstructured":"Vegt E.; de Jong M.; Wetzels J.F.; Masereeuw R.; Melis M.; Oyen W.J.; Gotthardt M.; Boerman O.C.; Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010,51(7),1049-1058","journal-title":"J Nucl Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12565-016-0369-3","volume":"92","author":"Otani N.","year":"2017","unstructured":"Otani N.; Ouchi M.; Hayashi K.; Jutabha P.; Anzai N.; Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. Anat Sci Int 2017,92(2),200-206","journal-title":"Anat Sci Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/nep.12838","volume":"22","author":"Severin M.J.","year":"2017","unstructured":"Severin M.J.; Hazelhoff M.H.; Bulacio R.P.; Mamprin M.E.; Brandoni A.; Torres A.M.; Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions. Nephrology (Carlton) 2017,22(8),642-648","journal-title":"Nephrology (Carlton)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0006-2952(03)00466-0","volume":"66","author":"Habu Y.","year":"2003","unstructured":"Habu Y.; Yano I.; Takeuchi A.; Saito H.; Okuda M.; Fukatsu A.; Inui K.; Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: Roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem Pharmacol 2003,66(6),1107-1114","journal-title":"Biochem Pharmacol"},{"key":"ref=22","first-page":"177","volume":"41","author":"Trejtnar F.","year":"2000","unstructured":"Trejtnar F.; Laznicek M.; Laznickova A.; Mather S.J.; Pharmacokinetics and renal handling of 99mTc-labeled peptides. J Nucl Med 2000,41(1),177-182","journal-title":"J Nucl Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13550-020-0599-1","volume":"10","author":"Altai M.","year":"2020","unstructured":"Altai M.; Garousi J.; Rinne S.S.; Schulga A.; Deyev S.; Vorobyeva A.; On the prevention of kidney uptake of radiolabeled DARPins. EJNMMI Res 2020,10(1),7","journal-title":"EJNMMI Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.peptides.2012.01.007","volume":"33","author":"Zhu Y.","year":"2012","unstructured":"Zhu Y.; Meng Q.; Wang C.; Liu Q.; Sun H.; Kaku T.; Liu K.; Organic anion transporters involved in the excretion of bestatin in the kidney. Peptides 2012,33(2),265-271","journal-title":"Peptides"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00259-007-0519-x","volume":"34","author":"Stahl A.R.","year":"2007","unstructured":"Stahl A.R.; Wagner B.; Poethko T.; Perutka M.; Wester H.J.; Essler M.; Heemann U.; Schwaiger M.; Lutz J.; Renal accumulation of [111In]DOTATOC in rats: Influence of inhibitors of the organic ion transport and diuretics. Eur J Nucl Med Mol Imaging 2007,34(12),2129-2134","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1021\/acs.molpharmaceut.8b01091","volume":"16","author":"Xiong C.","year":"2019","unstructured":"Xiong C.; Yin D.; Li J.; Huang Q.; Ravoori M.K.; Kundra V.; Zhu H.; Yang Z.; Lu Y.; Li C.; Metformin reduces renal uptake of radiotracers and protects kidneys from radiation-induced damage. Mol Pharm 2019,16(2),808-815","journal-title":"Mol Pharm"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220113101004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200198\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220113101004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:21:20Z","timestamp":1692037280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200198\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200223666220113101004","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}